Psyence Biomedical (PBM) vs Quantum Biopharma (QNTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Quantum Biopharma (QNTM) has outperformed Psyence Biomedical (PBM) over the past year, losing 80.3% versus a loss of 97.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PBM | QNTM |
|---|---|---|
| Share price | $5.02 | $3.01 |
| Market cap | — | $19.35M |
| 1-day change | -1.95% | -3.22% |
| YTD return | -82.59% | -57.40% |
| 1-year return | -97.05% | -80.28% |
| 5-year return | — | -96.65% |
| EPS (TTM) | $-12.56 | $-4.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $150.78 | $16.36 |
| 52-week low | $1.92 | $2.07 |
| Distance from 52-week high | -96.67% | -81.60% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +307.64% |
| Average volume | 94.85K | 205.30K |
| Shares outstanding | — | 6.43M |
| Employees | 12 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QNTM has outperformed PBM by 16.8 percentage points over the past year.
About Psyence Biomedical
PBM stock →Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Quantum Biopharma
QNTM stock →Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments.
Health Care · Biotechnology: Pharmaceutical Preparations
PBM vs QNTM FAQ
Which stock has performed better over the past year, PBM or QNTM?
QNTM returned -80.28% over the past 12 months, compared with -97.05% for PBM (price return, excluding dividends). Past performance does not predict future results.
Are Psyence Biomedical and Quantum Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.